Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort


  • Thomas Bettuzzi Service de Dermatologie, Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor, Université Paris-Est, Créteil, France
  • Hervé Bachelez
  • Marie Beylot-Barry
  • Hugo Arlégui
  • Carle Paul
  • Manuelle Viguier
  • Emmanuel Mahé
  • Nathalie Beneton
  • Denis Jullien
  • Marie-Aleth Richard
  • Pascal Joly
  • Florence Tubach
  • Alain Dupuy
  • Emilie Sbidian
  • Olivier Chosidow




psoriasis, drug survival, treatments, biologics, apremilast


Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheumatic drugs (bDMARDs) or synthetic disease-modifying antirheumatic drugs (sDMARDs). The aim of this study was to determine whether the increasing number of available systemic treatments for psoriasis affects drug survival over time. Patients were selected from the PsoBioTeq cohort, a French prospective observational cohort enrolling patients with moderate to severe psoriasis. All patients initiating a first bDMARD or sDMARD were included. The primary outcome was comparison of drug survival over time. A multivariate Cox proportional hazard ratio model was computed. A total of 1,866 patients were included; 739 females (39%), median age 47 years. In the multivariate Cox model, no association was found between the calendar year of initiation and drug survival (hazard ratio) overlapping from 0.80 (0.42–1.52) to 1.17 (0.64–2.17), p = 0.633). In conclusion, drug survival in psoriasis is not affected by the year of initiation.


Download data is not yet available.


Grodner C, Sbidian E, Weill A, Mezzarobba M. Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database. J Eur Acad Dermatol Venereol 2021; 35: 411-416.

https://doi.org/10.1111/jdv.16566 DOI: https://doi.org/10.1111/jdv.16566

Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM, Identification and management of psoriasis and associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.

https://doi.org/10.1038/jid.2012.339 DOI: https://doi.org/10.1038/jid.2012.339

Sbidian E, Le Cleach L, Trinquart L, Do G, Hughes C, Naldi L, et al. Systemic pharmacological treatments for chronic plaque psoriasis. Cochrane Skin Group, editor. Cochrane Database Syst Rev 2015 Feb 16 [cited 2020 Nov 1]; Available from: http://doi.wiley.com/10.1002/14651858.CD011535.

https://doi.org/10.1002/14651858.CD011535 DOI: https://doi.org/10.1002/14651858.CD011535

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1: CD011535.

https://doi.org/10.1002/14651858.CD011535.pub3 DOI: https://doi.org/10.1002/14651858.CD011535.pub3

Lin P-T, Wang S-H, Chi C-C. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep 2018; 8: 16068.

https://doi.org/10.1038/s41598-018-34293-y DOI: https://doi.org/10.1038/s41598-018-34293-y

Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; 135: 2632-4260.

https://doi.org/10.1038/jid.2015.208 DOI: https://doi.org/10.1038/jid.2015.208

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol 2020; 183: 294-302.

https://doi.org/10.1111/bjd.18981 DOI: https://doi.org/10.1111/bjd.18981

Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García F-J, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol 2016; 30: 1942-1950.

Sbidian E, Mezzarobba M, Weill A, Coste J, Rudant J. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2019; 180: 86-93.

https://doi.org/10.1111/bjd.16809 DOI: https://doi.org/10.1111/bjd.16809

Shalom G, Cohen AD, Feldhamer I, Comaneshter D, Freud T, Pavlovsky L. Drug survival in patients with psoriasis is associated with the availability of biologic medications. J Eur Acad Dermatol Venereol 2020; 34: 1524-1528.

https://doi.org/10.1111/jdv.16205 DOI: https://doi.org/10.1111/jdv.16205

Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT, Beylot-Barry M, Bachelez H, Beneton N, et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol 2020; 34: 293-300.

https://doi.org/10.1111/jdv.15878 DOI: https://doi.org/10.1111/jdv.15878

Sbidian E, Giboin C, Bachelez H, Paul C, Beylot-Barry M, Dupuy A, et al. Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the PsoBioTeq cohort. J Eur Acad Dermatol Venereol 2017; 31: 2046-2054.

https://doi.org/10.1111/jdv.14406 DOI: https://doi.org/10.1111/jdv.14406

Graier T, Salmhofer W, Jonak C, Weger W, Kölli C, Gruber B, et al. Biologic drug survival rates in the era of anti-Il-17 antibodies: a time period-adjusted registry analysis. Br J Dermatol 2021; 184: 1094-1105.

https://doi.org/10.1111/bjd.19701 DOI: https://doi.org/10.1111/bjd.19701

Phan C, Beauchet A, Burztejn A-C, Severino-Freire M, Barbarot S, Girard C, et al. Biological treatments for paediatric psoriasis: a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1984-1992.

https://doi.org/10.1111/jdv.15579 DOI: https://doi.org/10.1111/jdv.15579

Sbidian E, Billionnet C, Weill A, Maura G, Mezzarobba M. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database. Br J Dermatol 2020; 182: 690-697.

https://doi.org/10.1111/bjd.18047 DOI: https://doi.org/10.1111/bjd.18047

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37-49.

https://doi.org/10.1016/j.jaad.2015.03.049 DOI: https://doi.org/10.1016/j.jaad.2015.03.049

Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 2014; 28: 907-914.

https://doi.org/10.1111/jdv.12208 DOI: https://doi.org/10.1111/jdv.12208

Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509-519.

https://doi.org/10.1111/bjd.16102 DOI: https://doi.org/10.1111/bjd.16102



How to Cite

Bettuzzi, T., Bachelez, H., Beylot-Barry, M., Arlégui, H., Paul, C., Viguier, M., Mahé, E., Beneton, N., Jullien, D., Richard, M.-A., Joly, P., Tubach, F., Dupuy, A., Sbidian, E., & Chosidow, O. (2022). Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort. Acta Dermato-Venereologica, 102, adv00665. https://doi.org/10.2340/actadv.v101.566





Most read articles by the same author(s)

1 2 3 4 5 > >>